Cover Image
市場調查報告書

高磷酸鹽血症:開發平台分析

Hyperphosphatemia - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213117
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
高磷酸鹽血症:開發平台分析 Hyperphosphatemia - Pipeline Review, H2 2015
出版日期: 2015年07月15日 內容資訊: 英文 82 Pages
簡介

高磷酸鹽血症是指血清中磷酸鹽的濃度異常高的狀態,是因為磷酸鹽攝取的增加,磷酸鹽排放的減少,以及細胞將磷酸鹽由細胞內移往細胞外發生障礙造成。常見的症狀有倦怠感,呼吸急促,食慾不振,嘔吐,睡眠障礙等。治療法包含利尿劑或磷結合劑等。

本報告提供高磷酸鹽血症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

高磷酸鹽血症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

按開發中的產品:大學/研究機關

開發治療藥的企業

  • 3SBio Inc.
  • Ardelyx, Inc.
  • Galenica Ltd.
  • Medice Arzneimittel Putter GmbH & Co. KG
  • OPKO Health, Inc
  • Panion & Bf Biotech Inc
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.
  • Toray Industries

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • colestilan chloride
  • CPAM-11
  • fermagate
  • ferric citrate
  • calcium succinate
  • JPH-101
  • niacinamide
  • PDX-003
  • PT-20
  • RDX-002
  • sevelamer carbonate
  • Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia
  • Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD
  • SPI-014
  • succharated ferric oxide
  • tenapanor hydrochloride
  • TRK-390
  • VS-501
  • VS-505

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6931IDB

Summary

Global Markets Direct's, 'Hyperphosphatemia - Pipeline Review, H2 2015', provides an overview of the Hyperphosphatemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperphosphatemia Overview
  • Therapeutics Development
    • Pipeline Products for Hyperphosphatemia - Overview
    • Pipeline Products for Hyperphosphatemia - Comparative Analysis
  • Hyperphosphatemia - Therapeutics under Development by Companies
  • Hyperphosphatemia - Therapeutics under Investigation by Universities/Institutes
  • Hyperphosphatemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hyperphosphatemia - Products under Development by Companies
  • Hyperphosphatemia - Products under Investigation by Universities/Institutes
  • Hyperphosphatemia - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Ardelyx, Inc.
    • Galenica Ltd.
    • Medice Arzneimittel Putter GmbH & Co. KG
    • OPKO Health, Inc.
    • Panion & Bf Biotech Inc
    • Sanofi
    • Spectrum Pharmaceuticals, Inc.
    • Toray Industries, Inc.
  • Hyperphosphatemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • colestilan chloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CPAM-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fermagate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ferric citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • calcium succinate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JPH-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • niacinamide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PDX-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PT-20 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RDX-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sevelamer carbonate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target Phosphate for Hyperphosphatemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-014 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • succharated ferric oxide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tenapanor hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRK-390 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VS-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VS-505 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hyperphosphatemia - Recent Pipeline Updates
  • Hyperphosphatemia - Dormant Projects
  • Hyperphosphatemia - Discontinued Products
  • Hyperphosphatemia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology
      • Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
      • Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis
      • Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
      • Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms
      • Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia
      • Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate
      • Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
      • Oct 23, 2014: Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
      • Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperphosphatemia, H2 2015
  • Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Hyperphosphatemia - Pipeline by 3SBio Inc., H2 2015
  • Hyperphosphatemia - Pipeline by Ardelyx, Inc., H2 2015
  • Hyperphosphatemia - Pipeline by Galenica Ltd., H2 2015
  • Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H2 2015
  • Hyperphosphatemia - Pipeline by OPKO Health, Inc., H2 2015
  • Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H2 2015
  • Hyperphosphatemia - Pipeline by Sanofi, H2 2015
  • Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
  • Hyperphosphatemia - Pipeline by Toray Industries, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H2 2015
  • Hyperphosphatemia - Dormant Projects, H2 2015
  • Hyperphosphatemia - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Hyperphosphatemia, H2 2015
  • Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top